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measure of adherence. Expecting a population targeted for cognitive decline to self-report their adherence is flawed.
The intervention Each intervention component is described, however, the evidence and theory supporting the combination of these intervention components is lacking and not reflected in the process evaluation thus the likely effective/ineffective components cannot be determined from this pilot study. I would prefer to see a logic model.
The choice of a process outcome (change in med administration times) is unlikely to be attractive to research funding bodies. The feasibility of collecting patient orientated outcomes should be considered.
Process evaluation
There is no reference to the development and evaluation of a training package or testing intervention fidelity.
REVIEWER
Judy Mullan University of Wollongong, Australia REVIEW RETURNED 30-Oct-2018
GENERAL COMMENTS
Thank you for the opportunity to review this submission, which I found interesting to read. My view is that the submission is publishable. However, prior to consideration for publication, I recommend some minor revisions. To help guide these minor revisions, I have included a number of comments/recommendations regarding different sections of the manuscript. Title: The title of the manuscript is very long and may need to be reviewed, especially since it appears that not all clients included in the study were in fact 'older people with cognitive and related functional decline' as suggested in the title. Abstract: Overall this section is well written. However, I am not convinced that the primary and secondary outcomes (as stated in the abstract) will be able to improve an understanding of how complex regimens contribute to the social, psychological and physical burden of medication administration among older people receiving community-based home care services.
Main Text: Introduction: My suggestion would be to revisit and revise this entire section which currently includes a lot of information which appears to be included as a list of studies, arguments and/or ideas rather than a critical synthesis of the background evidence. It also appears that over 25% of the included references are either co-authors or affiliates of the submission's authors. There are a number of other Australian and UK researchers (e.g. Gillespie et al and Maidment et al) which may be worthwhile considering. There appears to be a disconnect between the title of the manuscript and the stated objective of the pilot and feasibility study (page 8 lines 15-18).
Methods:
More information is required under the study design subheading about the purpose of the qualitative component and who will be included in this phase of the study.
As currently presented, the purpose of the governance committee is unclear.
Study participants described in this section appear to be somewhat different to those described in the title and the study objective. It is also not clear whether or not these participants will have been prescribed polypharmacy (≥5 medications/day) and/or whether culturally and linguistically diverse backgrounds participants were excluded from the study.
While I understand that the protocol papers typically report on planned studies, they can also report on ongoing studies. I would therefore suggest that the tense used in this section of the manuscript be revisited, given that some of the dates included are over 4 months old, particularly under the recruitment and consent process subheading.
It would be useful for the authors to describe why they used the Dementia Friendly Language guide, given that many of the participants were or will not be cognitively impaired. I don't see this as a problem, but feel that it should be explained in the text.
With regard to the Baseline Data collection, is it fair to assume that only one research nurse will be responsible for collecting all data for each participant, regardless of whether or not they are residing in metropolitan or rural SA locations?
While the quality and quantity of the data collected at baseline and four months post study (Table 1) are impressive, I'm still a little uncertain if they will be able to inform social, psychological and the physical burden of medication administration as stated in the abstract and the discussion section of the manuscript. I'm also unsure how the study will be collecting ambulance call out data. Will the researchers have access to SA Ambulance data or will this be reliant on participant self-report data or information received from the health care providers (e.g. GP, pharmacist or community based home care provider).
The HMR intervention is a good idea. However, does this mean that participants who have had a HMR within the previous 12 -24 months are exempt from the study?
The wording in the following sentences [page 18 (lines 1-14)] suggest that the stakeholders and committee members amended the MRS GRACE tool for use in a RAC setting rather than a community setting and will need to be revised: "Stakeholders included members of the expert panel who informed the development of MRS GRACE, and members of the research governance committee and stakeholder reference committee for a cluster randomised controlled trial focusing on medication simplification in the residential aged care setting.27 Minor revisions to the wording of the MRS GRACE tool and associated explanatory statement were made based on consultation with and feedback from the expert panel."
It is not quite clear from the information provided under the Qualitative subheading (page 22 lines 28-47) how many focus groups will be conducted. It would also be good to clarify if the "consumers" referred to in this section, are in fact the study participants or clients as interchangeably referred to in the manuscript.
REVIEWER

Toine Egberts
University Medical Center Utrecht/ Utrecht University The Netherlands REVIEW RETURNED 15-Dec-2018
GENERAL COMMENTS
Simplifying complex medication regimens for older people with cognitive and related functional decline receiving communitybased home care services: protocol for a pilot and feasibility study Manuscript ID bmjopen-2018-025345 General remarks First of all, I would like to express the importance of this topic.
Complex medication regimens are prone to errors in medication use, especially among older people with cognitive impairment. The clinical value of an implicit screening tool to facilitate simplification of drug regimens is therefore indeed relevant. The involvement of care consumers in evaluating such a tool is essential. I would like to stress that the participation of Care Reference Groups, which includes care consumers, is a big plus of the study design. Furthermore, my compliments for the structure of the manuscript, which makes it easy to read.
Although the study protocol of the pilot is interesting to read, I would like to remark that publication of the study protocol of the planned RCT as follow-up of this pilot study would be of more interest.
Major points There are, however, a few major points of concern.
Primary outcome -Page 5, line 24-26. Title, introduction, aim, and primary outcome are not entirely synchronized. For example the title mentions "medication complexity". In the introduction, it is stated that 'medication regimen complexity can arise due to the number of medications, multiple daily dosing, and special instructions with regards to food and specific time of day.' In contrast, it seems that the primary outcome of this study only covers the part that affects the 'multiple daily dosing' and therefore the primary outcome does not match entirely with the title and this part of the introduction to optimize complex medication regimens. ('The primary outcome will be the change in the number of medication administration times over a 24-hour period for regular medications at four months post-study entry' page 18, line 51-53) In addition, the interventions mentioned on page 6, line 49-59, as examples for drug regimen simplifications are not mentioned in the primary outcome. I suggest to synchronize title, introduction, aim, intervention and primary study outcome. In addition, an example (i.e. medication regimen prior and after intervention) should be added to illustratie the primary outcome measurement
Patient recruitment -Page 20, line 34. 'A sample size of 50 participants was chosen…' The authors do not provide sufficient background information that supports the number of patients needed to assess the feasibility of the pilot. In addition, the selection mechanism of the recruitment should be explained in more detail (page 9, line 45-46 'Research nurses will liaise with community-based home care provider staff to identify eligible clients.'). A commonly used recruitment strategy is to enroll consecutive patients in a certain period of time that match the inclusion criteria, but the recruitment process remains unclear to the reader. Therefore, this raises questions like how (and how many) participants diagnosed with and without dementia were selected.
Study design -Page 3, line 24 / page 7 line 28. 'This pilot and feasibility study will apply a 'pre-post design'. In my opinion, the paper describes an intervention (without a control arm). Therefore, the term 'pre-post design' is not appropriate and confuses the reader. Evaluation of feasibility Since this is a feasibility study, it would be appropriate if the authors would add their criteria for evaluating and judging the feasibility.
Minor points There are however a few minor points to address Title I would suggest to rephrase the title to make it more attractive to readers and to cover the essence of the paper. The primary aim of the study is to describe an intervention. Therefore, this should be part of the title ('The effect of a multicomponent intervention to….'). In addition, changing the part 'with cognitive and related functional decline' into 'with dementia' would probably better target the study population.
Page 6, line 16 First paragraph; numbers from Sweden seem to be a bit randomly selected, as the study will be conducted in Australia.
Abstract
It helps readers to determine the scope of the paper if the authors would mention in the abstract that the pilot study is a feasibility study in preparation to an RCT.
Page 8, line 26-39
The Care Reference Groups 'comprise of people who either receive services from the community-based home care service provider or have a family member who receive these services'. It might be useful to get more detailed information about the composition of this group (e.g. how many care receivers?)
Page 9, line 30 The term 'dementia' and 'cognitive impairment/decline' are both used, seemingly interchangeable, which might confuse readers.
Page 9, line 24-25 'Clients will be eligible if they are prescribed medications two or more times daily'. Does this criteria mean that every patient who takes medication ≥2 times daily is eligible for inclusion, regardless of the number of medication (for instance, patients who use monotherapy of 2dd500mg metformin would match the inclusion criteria)?
Page 9, line 22-30 In this section, it is stated that 'those deemed by health professionals and caregivers to be medically unstable (e.g. experiencing delirium) will be excluded. Clients may also be excluded for any other reason at the discretion of their regular treating clinicians or informal caregivers'. Please consider how this will affect the representativeness of the study population (selection bias) and therefore the conclusion concerning the 'feasibility'.
Page 9, line 43. '…the first participant will be enrolled on 22 August 2018.' Rewrite in past tense.
Page 12-15, table 1. Many questionnaires are used for data collections. For some of them, justification is provided (for example, SAPS and QoL-AD are recommended in the Australian Government Dementia Outcomes Measurement Suite), but some of them lack an explanation (for example, to assess medication adherence the SEAMS-scale is used, why is this scale used?). Please provide a more detailed justification for each of the chosen measurement tools.
Page 15, line 16. The first step of the intervention consists of medication reconciliation. It seems that this important step of the intervention could have been carried out in a more structured and standardized way, for example by using a tool like SHIM (see: Structured history taking of medication use reveals iatrogenic harm due to discrepancies in medication histories in hospital and pharmacy records A. Clara Drenth-van Maanen et al. J Am Geriatr Soc. 2011 Oct; 59(10):1976-7) . The authors could reflect on this in their discussion.
Page 16, line 51. Please provide as supplementary data the modified version of the implicit structured MRS GRACE-tool, which was used in this study.
Page 20, line 9 The time of the project pharmacist will be measured. According to the protocol, the 'registered nurse' and the community pharmacist/GP play an important role as well in the implementation of the intervention. Will this time be measured as well, in order to provide a more accurate overview of the overall time investment? To what extent will the impact on healthcare costs be evaluated?
VERSION 1 -AUTHOR RESPONSE
REVIEWER 1
Reviewer comment 1. The introduction provides a coherent rationale for medication regimen simplification potentially enhancing adherence. However, medication adherence is a multi-faceted behaviour; the focus of the introduction appears to be unintentional non-adherence despite significant body of literature demonstrating that intentional non-adherence arising from perceptual barriers is prevalent in all populations including older people. The introduction appears to be stereotyping older people as being non-adherent due to forgetfulness and confusion rather than making a conscious decision to deviate from prescribed directions.
Response: We have revised the manuscript introduction to focus on medication simplification rather than non-adherence. The main focus of this pilot study is to assess feasibility of conducting a trial to reduce the number of medication administration times. We do not seek to stereotype older people as being non-adherent. Instead, medication adherence is a secondary outcome that was added on request of the stakeholder reference group for this study, which included consumers and carers.
Reviewer comment 2. It would be useful if the study objectives could be explicitly stated prior to or at the beginning of the methods. This will enable the rationale for each piece of data collected to be more easily linked with these objectives. I'd specifically like to see the objectives for the process evaluation.
Response: We have added the study objectives at the end of the introduction section of the revised manuscript as suggested by the reviewer.
We have revised the study aim and primary and secondary outcome measures to reflect that this is a pilot and feasibility study. This is consistent with the principles outlined by Eldridge et al. and the CONSORT extension for pilot and feasibility trials (i.e. to assess the feasibility of further development of the intervention and suitability to implement as an RCT, rather than assessing the effectiveness or efficacy of the intervention delivered). We have removed the text referring to a process evaluation because the revised aim, objectives and primary outcome sections of the manuscript now relate to assessment of study feasibility, which includes recruitment and retention rates, protocol adherence and stakeholder acceptability.
Reviewer comment 3. The protocol outlines a feasibility and pilot with a before and after design. The intention is for the definitive study to be randomised which is an important parameter influencing recruitment thus absence of randomisation for the pilot phase needs some justification.
We now explain in paragraph 2 of the discussion section that this study did not pilot the randomisation process. Instead, the study was conducted to establish the probable 'active components' of the intervention and to determine appropriate and acceptable outcome measures so that these parameters can be measured during the during the subsequent trial. Strategies such as offering the intervention to participants in the control group of a subsequent RCT at the end of the trial (e.g. a randomised waiting list study)* may mitigate the impact of randomisation on recruitment rates for the RCT. Reviewer comment 4. The protocol states the following: "All information and consent materials will be written using the Dementia Australia Guide to Dementia Friendly Language. Research nurses will be trained using the Dementia Australia 'Talk to Me' tips for talking to people living with dementia." I also note that self-reporting is the intended measure of adherence. Expecting a population targeted for cognitive decline to self-report their adherence is flawed.
Response: Adherence to the medication regimen will be assessed with the Self-Efficacy for Appropriate Medication use Scale (SEAMS). Adherence is a secondary outcome. Reference group members recommended assessing whether simplification activities had an impact on adherence among people living in the community. We agree that not all participants may be able to self-report their medication adherence. We have added this as a limitation to our study. However, previous studies of people with and without dementia in aged care settings have demonstrated a considerable proportion of people with dementia are able to self-report outcomes (e.g. 64% of residents were able to self-report quality of life in a previous study conducted in residential aged care).* *Reference: Beer C, et al. PLoS One. 2010; 5(12): e15621.
We added the following text to the discussion section of the manuscript:
"Asking people to self-report medication self-efficacy and adherence is another potential study limitation. However, previous studies of people with and without dementia in aged care settings have demonstrated a considerable proportion of people with dementia are able to self-report outcomes.46 In the present study, a third-party informant may be interviewed when a participant is not able to undertake assessments themselves. Research nurses will also liaise with the participant's community pharmacist to provide a recent dispensing history and this will aid insight into adherence to prescription medications."
We have also made minor amendments to the section discussing the Dementia Australia language guide in response to Reviewer 2 comment 10.
Reviewer comment 5. The intervention: Each intervention component is described, however, the evidence and theory supporting the combination of these intervention components is lacking and not reflected in the process evaluation thus the likely effective/ineffective components cannot be determined from this pilot study. I would prefer to see a logic model.
The pilot and feasibility study has been designed in accordance with the phased approach to evaluation of complex interventions.* We believe that each intervention component is consistent with the process of medication simplification. We believe there is a strong clinical and ethical rationale supporting these combinations of interventions. Before simplifying a regimen, it is important to have an accurate and up-to-date medication list and this will be obtained through the process of medication reconciliation. It is also important to assess a person's capacity to self-manage their medication regimen before recommending changes to a person's medication administration routine. These principles are further described in our research paper describing the development and validation of the MRS GRACE tool that was adapted for use in this study.
*Reference: Campbell M, et al. BMJ 2000;321:694-6.
Reviewer comment 6: The choice of a process outcome (change in med administration times) is unlikely to be attractive to research funding bodies. The feasibility of collecting patient orientated outcomes should be considered.
Response: We thank the Reviewer for their comment but do not agree with this assertion. The choice of primary outcome was based on extensive consultation with consumers and aged care providers. This and other strategies to reduce the burden of medication administration have attracted a high level of consumer support. Indeed, our study has already been reviewed and funded by Australia's National Health and Medical Research Council Cognitive Decline Partnership Centre. We have had strong support stakeholder support for this intervention at all stages of the research process, and the study involves assessing patient-orientated outcomes such as satisfaction and quality of life.
Reviewer comment 7: There is no reference to the development and evaluation of a training package or testing intervention fidelity.
Response: As discussed in the response to Reviewer 1 comment 2 (above), the revised aim, objectives and primary outcome sections of the manuscript now relate to assessment of study feasibility, which includes recruitment and retention rates, protocol adherence and stakeholder acceptability. Please refer to the revised primary outcome section which discusses the assessment of protocol adherence (the degree to which the project was delivered as intended, which incorporates intervention fidelity).
Our training package was adapted from our previous RCT investigating medication simplification in residential aged care. The research nurses working on the pilot and feasibility study are the same research nurses involved with our previous RCT. Many of the assessments are the same as the previous RCT. We added the following text to the 'Recruitment and consent process' section of the revised manuscript:
"Research nurses will be contracted by the community-based home care provider organisation and will therefore have good knowledge of organisational processes, policies and procedures. A training package adapted from a related study conducted in residential aged care12 was used to train the research nurses in the consent process for the present study, and to train the research nurses and project pharmacist to use the data collection tools and administer assessments."
Reviewer comment 1: Thank you for the opportunity to review this submission, which I found interesting to read. My view is that the submission is publishable. However, prior to consideration for publication, I recommend some minor revisions. To help guide these minor revisions, I have included a number of comments/recommendations regarding different sections of the manuscript.
Response: Thank you for taking the time to review and comment on our submission.
Reviewer comment 2: Title: The title of the manuscript is very long and may need to be reviewed, especially since it appears that not all clients included in the study were in fact 'older people with cognitive and related functional decline' as suggested in the title.
Response: We have revised the title based on this comment and the title suggestions provided by Reviewer 3 (comment 10). The revised title is: "Protocol for a non-randomised pilot and feasibility study evaluating a multicomponent intervention to simplify medication regimens for people receiving community-based home care services".
Reviewer comment 3: Abstract: Overall this section is well written. However, I am not convinced that the primary and secondary outcomes (as stated in the abstract) will be able to improve an understanding of how complex regimens contribute to the social, psychological and physical burden of medication administration among older people receiving community-based home care services.
Response: Thank you, we agree this pilot and feasibility study may not improve understanding of all these aspects of medication administration. We have amended this sentence to read: "This study will enable an improved understanding of medication administration among older people…"
Reviewer comment 4: Introduction: My suggestion would be to revisit and revise this entire section which currently includes a lot of information which appears to be included as a list of studies, arguments and/or ideas rather than a critical synthesis of the background evidence. It also appears that over 25% of the included references are either co-authors or affiliates of the submission's authors. There are a number of other Australian and UK researchers (e.g. Gillespie et al and Maidment et al) which may be worthwhile considering.
Response: We have made considerable edits to the introduction section of the revised manuscript based on comments from all three reviewers. We have reviewed the included references in the paper and less than 25% are authored by us or our affiliates. We have reviewed other research papers, including those by Gillespie et al. and Maidment et al., and have cited relevant literature in the revised introduction as suggested.
Reviewer comment 5: There appears to be a disconnect between the title of the manuscript and the stated objective of the pilot and feasibility study (page 8 lines 15-18).
Response: We have revised the title, study aim, objectives and text in the 'Participants' section and these now align.
Reviewer comment 6: Methods: More information is required under the study design subheading about the purpose of the qualitative component and who will be included in this phase of the study.
Response: Further information about the purpose of the qualitative component is now provided in the study aim, study objectives and 'Primary Outcome' sections of the manuscript. In the revised 'Primary Outcome' section, we explain who will be invited to participate in the qualitative phase of the study.
Reviewer comment 7: As currently presented, the purpose of the governance committee is unclear.
Response: We clarified this in the revised manuscript, which now reads:
"The Project Governance Committee will comprise the chief investigators and nominated representatives from the organisation providing the community-based home care services. This committee will monitor compliance with the study protocol, data collection and data analysis throughout the study period."
Reviewer comment 8: Study participants described in this section appear to be somewhat different to those described in the title and the study objective. It is also not clear whether or not these participants will have been prescribed polypharmacy (≥5 medications/day) and/or whether culturally and linguistically diverse backgrounds participants were excluded from the study.
Response: We have revised the title, study aim, objectives and text in the 'Participants' section and these now align. We have clarified the inclusion criteria relating to medication use (please see italicised text below and response to Reviewer 3 comment 15). We added a sentence to this section to clarify inclusion criteria. Participants need to be able to participate in structured assessments in English in order to participate in this study.
The revised text now reads:
"The participants will be 50 clients receiving Commonwealth Home Support Programme services or Home Care Packages in metropolitan and rural South Australia. Clients will be eligible if they are able to participate in structured assessments in English and prescribed medication(s) to be administered two or more times daily on a regular basis. This means that a client prescribed one medication twice per day on a regular basis is eligible to participate."
Reviewer comment 9: While I understand that the protocol papers typically report on planned studies, they can also report on ongoing studies. I would therefore suggest that the tense used in this section of the manuscript be revisited, given that some of the dates included are over 4 months old, particularly under the recruitment and consent process subheading.
Response: We first submitted this protocol paper to BMJ Open in early July 2018. We have rewritten the 'recruitment and consent process' section in past tense in the revised version as per suggestions from Reviewer 2 and Reviewer 3.
Reviewer comment 10: It would be useful for the authors to describe why they used the Dementia Friendly Language guide, given that many of the participants were or will not be cognitively impaired. I don't see this as a problem, but feel that it should be explained in the text.
Response: We anticipate the participants will include people with and without dementia. Approximately 1 in 5 older people that receive a community aged care package in Australia are living with dementia. Our research is funded by the National Health and Medical Research Council Cognitive Decline Partnership Centre. It is important to promote and adhere to best practice principles when speaking and writing about people living with dementia
In the revised manuscript, the text now reads: "The Dementia Australia Guide to Dementia Friendly Language was used when writing about dementia or the impact of supporting a person living with dementia.25 Research nurses were trained to use the principles outlined in the Dementia Australia 'Talk to Me' tips for talking to people living with dementia during discussions with people living with dementia and when administering the dementia severity rating scale.26 Using appropriate language which is accurate, respectful, inclusive, empowering and non-stigmatising is important when talking about dementia.25"
We also added a sentence to highlight the proportion of people receiving aged care services who are living with dementia in the methods section (this is the most recent data available): "In 2008, 17% of Australians receiving a government-subsidised community aged care service package were living with dementia.23"
Reviewer comment 11: With regard to the Baseline Data collection, is it fair to assume that only one research nurse will be responsible for collecting all data for each participant, regardless of whether or not they are residing in metropolitan or rural SA locations?
Response: We now refer to 'research nurses' consistently throughout the revised manuscript as two research nurses are involved in recruitment and data collection.
Reviewer comment 12: While the quality and quantity of the data collected at baseline and four months post study (Table 1) are impressive, I'm still a little uncertain if they will be able to inform social, psychological and the physical burden of medication administration as stated in the abstract and the discussion section of the manuscript.
Response: We have updated this sentence in line with the revisions made according to Reviewer 2 comment 3. The sentence now reads: This study will improve understanding of medication administration among older people…" Reviewer comment 13: I'm also unsure how the study will be collecting ambulance call out data. Will the researchers have access to SA Ambulance data or will this be reliant on participant self-report data or information received from the health care providers (e.g. GP, pharmacist or community-based home care provider).
Response: We aim to collect data from the South Australian Ambulance Service in addition to participant self-report and information from the person's GP and community-based home care provider where feasible. We have revised the data sources in Table 1 of the revised manuscript to specifically state "South Australian Ambulance Service records" to clarify the data source. We have also added a sentence to the discussion section regarding potential limitations with participant selfreport data in response to Reviewer 1 comment 4.
Reviewer comment 14: The HMR intervention is a good idea. However, does this mean that participants who have had an HMR within the previous 12 -24 months are exempt from the study?
Response: People who have received an HMR in the previous 12 to 24 months are still eligible for inclusion in the study. This is because our previous research has shown that medication simplification is not the main focus of a medication review. We added the following sentence to Table 1 to clarify: "People who have previously received an HMR are still eligible for inclusion in this study."
Reviewer comment 15: The wording in the following sentences [page 18 (lines 1-14) ] suggest that the stakeholders and committee members amended the MRS GRACE tool for use in a RAC setting rather than a community setting and will need to be revised: "Stakeholders included members of the expert panel who informed the development of MRS GRACE, and members of the research governance committee and stakeholder reference committee for a cluster randomised controlled trial focusing on medication simplification in the residential aged care setting.27 Minor revisions to the wording of the MRS GRACE tool and associated explanatory statement were made based on consultation with and feedback from the expert panel."
Response: We have revised the sentence, which now reads: "Stakeholders included members of the expert panel who informed the development of MRS GRACE, and members of the research governance committee and stakeholder reference committee for the pilot and feasibility study. Minor revisions to the wording of the MRS GRACE tool and associated explanatory statement to support application in the community setting were made based on consultation with and feedback from these stakeholders."
Reviewer comment 16: It is not quite clear from the information provided under the Qualitative subheading (page 22 lines 28-47) how many focus groups will be conducted. It would also be good to clarify if the "consumers" referred to in this section, are in fact the study participants or clients as interchangeably referred to in the manuscript.
Response: We made major revisions to this section, which is now discussed under the subheading 'primary outcome'. We will aim to involve 10-15 key stakeholders in the small focus groups or semistructured interviews rather than undertake a set number of focus groups.
In this section, and throughout the rest of the manuscript, we have updated terminology and the term 'client' is no longer used.
REVIEWER 3
Reviewer comment 1: General remarks. First of all, I would like to express the importance of this topic. Complex medication regimens are prone to errors in medication use, especially among older people with cognitive impairment. The clinical value of an implicit screening tool to facilitate simplification of drug regimens is therefore indeed relevant. The involvement of care consumers in evaluating such a tool is essential. I would like to stress that the participation of Care Reference Groups, which includes care consumers, is a big plus of the study design. Furthermore, my compliments for the structure of the manuscript, which makes it easy to read.
Response: Thank you for your positive feedback.
Reviewer comment 2: Although the study protocol of the pilot is interesting to read, I would like to remark that publication of the study protocol of the planned RCT as follow-up of this pilot study would be of more interest.
Response: Thank you, we intend to publish the study protocol for the RCT planned to follow this pilot study, should the RCT be feasible.
Reviewer comment 3: Primary outcome -Page 5, line 24-26. Title, introduction, aim, and primary outcome are not entirely synchronized. For example, the title mentions "medication complexity". In the introduction, it is stated that 'medication regimen complexity can arise due to the number of medications, multiple daily dosing, and special instructions with regards to food and specific time of day.' In contrast, it seems that the primary outcome of this study only covers the part that affects the 'multiple daily dosing' and therefore the primary outcome does not match entirely with the title and this part of the introduction to optimize complex medication regimens. ('The primary outcome will be the change in the number of medication administration times over a 24-hour period for regular medications at four months post-study entry' page 18, line 51-53)
Response: Medication simplification is one strategy to reduce complexity, but we recognise that it may not target all aspects of complexity. We have removed the definition and information relating to medication complexity from the introduction and focused more on number of administration times and medication simplification.
Reviewer comment 4: In addition, the interventions mentioned on page 6, line 49-59, as examples for drug regimen simplifications are not mentioned in the primary outcome.
Response: Our revised secondary outcome focuses on reducing the number of medication administration times. We know from our previous research that the majority of simplification recommendations involve changing administration times, with fewer recommendations focused on use of combination formulations or longer acting formulations. Recommendations to use combination or longer acting formulations may contribute to a reduced number of administration times, but may also reduce the total tablet burden. Hence, we have also added "total number of doses administered over a 24-hour period" as another secondary outcome measure in the revised manuscript.
Reviewer comment 5: I suggest to synchronize title, introduction, aim, intervention and primary study outcome. In addition, an example (i.e. medication regimen prior and after intervention) should be added to illustrate the primary outcome measurement.
Response: We have revised the title, introduction, study aim, objectives, text in the 'Participants' section, intervention, and primary and secondary study outcomes sections and these now align. Table 2 provides a hypothetical example to illustrate the secondary outcome measurement relating to a change in the number of medication administration times as requested by the reviewer.
Reviewer comment 6: Patient recruitment -Page 20, line 34. 'A sample size of 50 participants was chosen…' The authors do not provide sufficient background information that supports the number of patients needed to assess the feasibility of the pilot.
Response: The following text has been added under the sample size subheading of the manuscript:
"As this is a pilot and feasibility study, a formal sample size calculation is not required. We will aim to recruit a sample size of 50 participants to adequately assess feasibility across a diverse range of participants including those with and without a dementia diagnosis, different care needs or frailty status, and with or without informal carers. We estimate this sample size would be greater than 10% of the number of people required for a future RCT. This sample size is in keeping with the median target sample size of 30 (interquartile range (IQR) 20-45) people for pilot studies, 36 (IQR 25-50) people for feasibility studies and 49 (IQR 36-61) people for pilot and feasibility studies observed in an audit of 79 pilot and feasibility RCTs registered on the United Kingdom Clinical Research Network database in 2012.44"
Reviewer comment 7: In addition, the selection mechanism of the recruitment should be explained in more detail (page 9, line 45-46 'Research nurses will liaise with community-based home care provider staff to identify eligible clients.'). A commonly used recruitment strategy is to enrol consecutive patients in a certain period of time that match the inclusion criteria, but the recruitment process remains unclear to the reader. Therefore, this raises questions like how (and how many) participants diagnosed with and without dementia were selected.
Response: We confirm the recruitment strategy for the study was to enrol consecutive clients who matched the study inclusion criteria. We added the following under the 'Participants' section of the manuscript to clarify the recruitment process:
"Participant recruitment commenced on 16 July 2018 and the first participant was enrolled on 22 August 2018. Research nurses liaised with community-based home care provider staff to obtain a list of all clients receiving medication administration assistance who were potentially eligible. Research nurses then mailed information about the study to all clients receiving medication administration assistance. Research nurses then conducted follow-up telephone calls with all clients who were mailed information to determine eligibility for the study, provide verbal information about the study, and to seek written informed consent to participate."
We deleted the statement "The clients will be purposely sampled to include clients who are frail and non-frail, with and without functional impairment, and with and without dementia".
Reviewer comment 8: Study design -Page 3, line 24 / page 7 line 28. 'This pilot and feasibility study will apply a 'pre-post design'. In my opinion, the paper describes an intervention (without a control arm). Therefore, the term 'pre-post design' is not appropriate and confuses the reader.
Response: We now refer to the study as a non-randomised study as suggested by Eldridge et al.
(Reference 18) in the manuscript text and abstract. The study design now states: "This pilot and feasibility study is a non-randomised study and all participants will receive the intervention."
Reviewer comment 9: Evaluation of feasibility. Since this is a feasibility study, it would be appropriate if the authors would add their criteria for evaluating and judging the feasibility.
